We are a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined, high-margin specialty markets.
|May14||SteadyMed Reports Recent Developments, Financial Highlights and First Quarter 2015 Financial Results|
|May07||SteadyMed Submits Application for Orphan Drug Designation for Trevyent(R) For Pulmonary Arterial Hypertension|
|Apr22||SteadyMed Granted Additional U.S. Patent With Patent Term Extension|
In June, SteadyMed's Jonathan Rigby will be biking from London to Paris in support of PH. The 299 mile, 4 day route travels through English countryside, to the ferry from Dover to Calais. Once 'French side', the riders will push on cycling along French country lanes, finishing the nearly 300 mile trek at the Eiffel Tower. If you would like to learn more about the event, or are interested in supporting Jonathan and the PH Community, please follow this link.